Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants Ended

2024-512939-67-00 Mental health disorders 2025-05-10
A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma Ended

2024-513439-25-00 Relapsed/Refractory Multiple Myeloma 2025-04-30
A first-in-human study to learn about how safe the study drug is in healthy participants Ended

2024-517512-30-00 Cardiac arrhythmia 2025-04-28
Phase 1 trial of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2-T cell engager, in patients with CD123 positive relapsed/refractory (R/R) ac… Ended

2024-518831-12-00 CD123 positive R/R AML and intermediate risk, high risk 2025-04-15
Phase I single-blind clinical trial to evaluate the safety and local immune activation of a toll-like receptor 5 agonist (FLAMOD) administer… Ended

2024-515933-14-00 Pneumonia 2025-04-14
Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema Ended

2025-520514-64-00 Atopic Dermatitis 2025-04-04
A FIRST-IN-HUMAN PHASE I TRIAL OF OX118 IN HEALTHY VOLUNTEERS Ended

2024-515378-28-00 Immune system Diseases 2025-04-03
A trial in healthy participants to examine the safety, tolerability, and pharmacokinetics of orally administered FT751 Ended

2024-519998-19-00 Inflammatory diseases 2025-03-31
A clinical study of MK-7228 in healthy men (MK-7228-001) Ended

2024-520214-22-00 Atherosclerosis 2025-03-24
Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Ended

2024-511440-76-00 Cutaneous Squamous Cell Carcinoma 2025-03-20
Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors Ended

2024-513563-75-00 Metastatic or advanced malignant solid tumors 2025-03-20
A study to investigate safety, tolerability, pharmacokinetics and efficacy of REM0045392 compared with placebo in healthy participants Ended

2025-520454-11-00 Alzheimer 2025-03-20
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer Ended

2024-515607-19-00 Patients with suspected clear cell renal cell carcinoma 2025-03-19
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer Ended

2024-515608-38-00 Patients with prostate cancer with: -suspected metastas 2025-03-19
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended

2024-515391-12-00 Advanced Solid Tumors with AKT1 E17K Mutation 2025-03-15
TGD001 SAD study in healthy volunteers Ended

2024-514931-63-00 A Phase I randomized, double-blind, placebo-controlled 2025-03-14
A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Diffe… Ended

2022-503102-20-00 Advanced solid tumors 2025-03-10
A Study of ZW171 in Participants with Advanced or Metastatic Mesothelin Expressing Cancers Ended

2024-511119-11-00 Advanced or metastatic ovarian cancer, NSCLC, pancreati 2025-03-07
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults. Ended

2024-515285-14-00 Healthy Volunteers 2025-03-04
A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended

2024-512380-32-00 esophageal, gastric, or gastroesophageal junction adeno 2025-03-03
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced … Ended

2024-511259-16-00 Advanced Solid Tumors 2025-02-24
A Phase 1, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multi… Ended

2024-515549-40-00 neurological disease 2025-02-21
Phase 1 first-in-human, single and multiple dosing study of FB301 in healthy female subjects Ended

2024-517539-38-00 Women infertility 2025-02-13
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for … Ended

2023-509257-31-00 Alzheimer’s Disease in Individuals with Down Syndrome 2025-02-12